Addressing the Threat of Drug-Resistant Tuberculosis: A Realistic Assessment of the Challenge: Workshop Summary (2009)
Chapter: Appendix A: Agenda
Appendix A
Agenda
|
8:00–8:10 |
Objectives of the Workshop |
|
|
Gail Cassell, Eli Lilly and Company |
|
|
Workshop Chair |
|
8:10–9:40 |
Panel I: SETTING THE STAGE |
|
10-minute presentations followed by a 30-minute panel discussion |
|
|
|
Moderator: Kenneth Castro, Centers for Disease Control and Prevention |
|
|
Paul Nunn, World Health Organization Global Incidence of MDR TB |
|
|
Yanis Ben Amor, Earth Institute Underreported Threat of MDR TB in Africa |
|
|
Gerald Friedland, Tugela Ferry Care and Research Collaboration HIV/MDR-XDR TB: Implications |
|
Megan Murray, Brigham and Women’s Hospital Number of MDR TB and XDR TB Patients Receiving Treatment Today: Successes/Failures/Consequences |
|
|
|
Qian Gao, Shanghai Medical College Transmission of MDR TB |
|
|
Neel Gandhi, Tugela Ferry Care and Research Collaboration Transmission of XDR TB |
|
9:40–9:50 |
Break |
|
9:50–11:30 |
Panel II: HOW DID WE GET TO WHERE WE ARE TODAY: DIFFERENT PERSPECTIVES |
|
10-minute presentations followed by a 40-minute panel discussion |
|
|
|
Moderator: Richard Chaisson, Johns Hopkins University |
|
|
Edward Nardell, Brigham and Women’s Hospital Lack of Infection Control |
|
|
John Ridderhof, Centers for Disease Control and Prevention Laboratory Capacity: A Global Analysis |
|
|
Anne Goldfeld, Harvard School of Public Health Drug and Health Care Delivery: Cambodian and Ethiopian Perspectives |
|
|
Wieslaw Jakubowiak, WHO Country Office Russian Federation Fighting Drug Resistance in Russia: Challenges and Achievements |
|
|
Paul Zintl, Partners In Health Drug Supply: The Stop TB Partnership Perspective |
|
|
Ruth Levine, Center for Global Development Critical Role of Accurate Demand Forecasting: Lessons Learned from Malaria |
|
11:30–12:30 |
Lunch |
|
12:30–1:20 |
Keynote Address: The Research Path to Tuberculosis Control: An NIH Perspective |
|
|
Anthony Fauci, National Institute of Allergy and Infectious Diseases |
|
1:20–3:00 |
Panel III: ESSENTIAL BUILDING BLOCKS |
|
10-minute presentations followed by a 20-minute panel discussion |
|
|
|
Moderator: Leonard Sacks, Food and Drug Administration |
|
|
Dale Nordenberg and Hamish Fraser, Brigham and Women’s Hospital Knowledge Management (IT): What Do We Need and What Do We Have? |
|
|
David Persing, Cepheid, and Charles Daitch, Akonni Biosystems Point-of-Care Diagnostics: How Close Are We? |
|
|
Ann Ginsberg, TB Alliance TB Drug Development: Realities of the Pipeline |
|
|
Raymond Woosley, The Critical Path Institute Critical Path for Parallel Development of TB Point-of-Care Diagnostic and Drug Development |
|
|
Jeff Moe, Duke University What Are the Odds? Who Will Pay? What Are the Incentives? |
|
3:00–3:15 |
Break |
|
3:15–4:15 |
Panel III: A BLUEPRINT FOR ACTION |
|
|
Moderator: Peter Cegielski, Centers for Disease Control and Prevention |
|
|
Salmaan Keshavjee, Partners In Health The Plan: From Powder to Patient |
|
|
Discussants: |
|
|
Michael Kimerling, Bill and Melinda Gates Foundation Carol Nacy, Sequella, Inc. Iain Richardson, Eli Lilly and Company Caroline Ryan, U.S. Department of State Sarita Shah, Tugela Ferry Care and Research Collaboration Alexander Sloutsky, University of Massachusetts Martie Van der Walt, Medical Research Council South Africa Charles Wells, Otsuka |
|
4:15–5:30 |
Panel V: THE NEED FOR URGENCY |
|
15-minute presentations followed by 45-minutes of discussion |
|
|
|
Moderator: Jim Yong Kim, Partners In Health |
